Cytodyn Inc Discussion on Company's Trials and COVID19 on Crush the Street Call Transcript
Hello, everyone, and welcome in to CrushTheStreet.com. I'm Kenneth Ameduri, and I got a really interesting interview today.
We've really covered what has been going on with the virus, the lockdowns, especially as it pertains to the economy, the shutdowns of the restaurants, the businesses. But we're really going to approach it from a scientific angle today and speak to an expert who's tackling this from the remediation side, the medicinal side. And we're really going to understand what is going on with COVID, how serious it is, and what the doctors are doing to deal with maybe future waves, mutations, and whatnot. And I want to get that information from our next guest today.
We are going to be speaking with Dr. Nader Pourhassan, CEO of CytoDyn. The company's ticker symbol is CYDY, and this is a company set to submit a trial design to the FDA to compare the effectiveness of leronlimab versus Gilead's resdesivir (sic - "remdesivir"). So this will be a really interesting conversation today. Dr. Pourhassan, thank you for joining me.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
